An Epigenetic Biomarker Panel for Glioblastoma Multiforme Personalized Medicine through DNA Methylation Analysis of Human Embryonic Stem Cell-like Signature

摘要: Alterations of DNA methylation occur during the course both stem cell development and tumorigenesis. We present a novel strategy that can be used to stratify glioblastoma multiforme (GBM) patients through epigenetic states genes associated with human embryonic (hESC) identity in order 1) assess linkages between signatures these survival GBM patients, 2) delineate putative mechanisms leading poor prognosis some patient subgroups. A signature was established for stratifying into several hESC methylator The methylator-negative phenotype has demonstrated upregulation glioma (GSC) markers, is enriched one previously defined transcriptomic phenotypes-the mesenchymal phenotype. further identified refined 36 as gene panel, including SOX2, POU3F2, FGFR2, GAP43, NTRK2, NTRK3, NKX2-2, which are highly nervous system. Both outperformed O6-methylguanine-DNA methyltransferase (MGMT) test predicting patient's outcome. These findings were also validated an independent dataset patients. Furthermore, statistical analyses, examined significantly. Hypomethylation hESC-associated predicted poorer clinical outcome GBM, supporting idea activation contributes aggression. panel presented herein may developed assays stratification future personalized medicine interventions.